Nobelpharma Co., Ltd. - Product Pipeline Review - 2012

Date: July 16, 2012
Pages: 31
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ND7E7D36E37EN
Leaflet:

Download PDF Leaflet

  • Abstracts
  • Contents
Nobelpharma Co., Ltd. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Nobelpharma Co., Ltd. - Product Pipeline Review - 2012” provides data on the Nobelpharma Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Nobelpharma Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Nobelpharma Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Nobelpharma Co., Ltd. - Brief Nobelpharma Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Nobelpharma Co., Ltd. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Nobelpharma Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Nobelpharma Co., Ltd.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Nobelpharma Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Nobelpharma Co., Ltd. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Nobelpharma Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Nobelpharma Co., Ltd..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Nobelpharma Co., Ltd. and identify potential opportunities in those areas.
Keywords

Current R&D Portfolio of Nobelpharma Co., Ltd.; Nobelpharma Co., Ltd. - Key Therapeutics; Nobelpharma Co., Ltd. - Pipeline Overview and Promising Molecules; Nobelpharma Co., Ltd. - News; Nobelpharma Co., Ltd. - Latest Updates; Nobelpharma Co., Ltd. - Pipeline; Nobelpharma Co., Ltd. - Discontinued/Dormant Projects
Nobelpharma Co., Ltd. Snapshot
Nobelpharma Co., Ltd. Overview
Key Information
Key Facts
Nobelpharma Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Nobelpharma Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Nobelpharma Co., Ltd. – Pipeline Products Glance
Nobelpharma Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Nobelpharma Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Nobelpharma Co., Ltd. – Drug Profiles
Gliadel Wafer
Product Description
Mechanism of Action
R&D Progress
NPC-01
Product Description
Mechanism of Action
R&D Progress
NPC-05 Talc
Product Description
Mechanism of Action
R&D Progress
NPC-06
Product Description
Mechanism of Action
R&D Progress
NPC-09
Product Description
Mechanism of Action
R&D Progress
NPC-11
Product Description
Mechanism of Action
R&D Progress
Nobelpharma Co., Ltd. – Pipeline Analysis
Nobelpharma Co., Ltd. – Pipeline Products by Therapeutic Class
Nobelpharma Co., Ltd. – Pipeline Products By Target
Nobelpharma Co., Ltd. – Pipeline Products by Route of Administration
Nobelpharma Co., Ltd. – Pipeline Products By Mechanism of Action
Nobelpharma Co., Ltd. – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Nobelpharma Co., Ltd., Deals Summary
Nobelpharma Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Eisai Enters Into An Agreement With Nobelpharma
Alfresa Pharma Enters Into Partnership Agreement With Nobelpharma
Licensing Agreements
Nobelpharma Enters Into Licensing Agreement With Pfizer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Nobelpharma Co., Ltd., Key Information
Nobelpharma Co., Ltd., Key Facts
Nobelpharma Co., Ltd. – Pipeline by Indication, 2012
Nobelpharma Co., Ltd. – Pipeline by Stage of Development, 2012
Nobelpharma Co., Ltd. – Monotherapy Products in Pipeline, 2012
Nobelpharma Co., Ltd. – Phase III, 2012
Nobelpharma Co., Ltd. – Phase II, 2012
Nobelpharma Co., Ltd. – Phase I, 2012
Nobelpharma Co., Ltd. – Pipeline By Therapeutic Class, 2012
Nobelpharma Co., Ltd. - Pipeline By Target, 2012
Nobelpharma Co., Ltd. – Pipeline By Route of Administration, 2012
Nobelpharma Co., Ltd. – Pipeline Products By Mechanism of Action, 2012
Nobelpharma Co., Ltd., Deals Summary
Eisai Enters Into An Agreement With Nobelpharma
Alfresa Pharma Enters Into Partnership Agreement With Nobelpharma
Nobelpharma Enters Into Licensing Agreement With Pfizer

LIST OF FIGURES

Nobelpharma Co., Ltd. – Pipeline by Indication, 2012
Nobelpharma Co., Ltd. – Pipeline by Stage of Development, 2012
Nobelpharma Co., Ltd. – Monotherapy Products in Pipeline, 2012
Nobelpharma Co., Ltd. – Pipeline By Therapeutic Class, 2012
Nobelpharma Co., Ltd. – Pipeline By Route of Administration, 2012
Nobelpharma Co., Ltd. - Pipeline Products By Mechanism of Action, 2012

Ask Your Question

Nobelpharma Co., Ltd. - Product Pipeline Review - 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: